{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:37:33Z","timestamp":1783953453728,"version":"3.55.0"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T00:00:00Z","timestamp":1593907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Highly effective direct\u2010acting antivirals (DAAs) for Hepatitis C treatment are largely inaccessible in sub\u2010Saharan Africa. Data on treatment feasibility and outcomes in clinical settings are limited. We assessed the feasibility of achieving a high (\u226590%) cure rate with DAAs in six gastroenterology clinics in Cameroon.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with chronic Hepatitis C virus (HCV) infection were treated for 12 or 24\u00a0weeks with ledipasvir\/sofosbuvir, ledipasvir\/sofosbuvir\/ribavirin or sofosbuvir\/ribavirin, depending on the stage of liver disease and HCV genotype. The cure rate was defined as the proportion of patients with a sustained virological response 12\u00a0weeks after treatment completion (SVR12) among all treatment completers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 190 HCV RNA positive patients between September\u20102017 and August\u20102018, 161 (84.7%) of whom started treatment. 105 (65.2%) were female, median age was 61.3\u00a0years [IQR\u00a0=\u00a055.9\u201366.9] and 11 (6.8%) were HIV\u2010positive. Median plasma HCV RNA was 6.0 log<jats:sub>10 <\/jats:sub>IU\/mL [IQR\u00a0=\u00a05.6\u20136.4]. HCV genotypes identified were 1 (34.8%), 2 (13.7%), 4 (50.9%), 1 and 4 (0.6%); 46 (28.6%) strains of 160 single\u2010genotype infections were non\u2010subtypeable. Of 158 treatment completers, 152 (96.2%, 95%CI\u00a0=\u00a091.9\u201398.6%) achieved SVR12. Six patients did not achieve SVR12: five carried HCV with NS5A resistance mutations and one with NS5B resistance mutations. Three patients died before and two after treatment completion. The most common adverse events were asthenia (12.0%), headache (11.4%) and dizziness (18.9%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High cure rates of Hepatitis C with DAAs are achievable in clinical settings of Cameroon. However, the accessibility and provision of HCV screening, diagnosis, treatment, monitoring and care should be addressed for large\u2010scale implementation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13450","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T18:05:00Z","timestamp":1591380300000},"page":"1098-1109","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Achieving a high cure rate with direct\u2010acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi\u2010clinic demonstration project"],"prefix":"10.1111","volume":"25","author":[{"given":"Liza","family":"Coyer","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Public Health Service of Amsterdam Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oudou","family":"Njoya","sequence":"additional","affiliation":[{"name":"Research Laboratory on Viral Hepatitis and Health Communication University of Yaound\u00e9 I Yaound\u00e9 Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Njouom","sequence":"additional","affiliation":[{"name":"Centre Pasteur du Cameroun Yaound\u00e9 Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Mossus","sequence":"additional","affiliation":[{"name":"Research Laboratory on Viral Hepatitis and Health Communication University of Yaound\u00e9 I Yaound\u00e9 Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin Pierre","family":"Kowo","sequence":"additional","affiliation":[{"name":"Research Laboratory on Viral Hepatitis and Health Communication University of Yaound\u00e9 I Yaound\u00e9 Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Essomba","sequence":"additional","affiliation":[{"name":"Research Laboratory on Viral Hepatitis and Health Communication University of Yaound\u00e9 I Yaound\u00e9 Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Boers","sequence":"additional","affiliation":[{"name":"Joep Lange Institute Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Coutinho","sequence":"additional","affiliation":[{"name":"PharmAccess Foundation Amsterdam The Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Ondoa","sequence":"additional","affiliation":[{"name":"African Society for Laboratory Medicine Addis Ababa Ethiopia"},{"name":"Amsterdam Institute for Global Health and Development Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HEP C\u2010IMPACT Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30579-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208809"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_6_5_1","unstructured":"Progress report on access to hepatitis C treatment:focus on overcoming barriers in low\u2010 and middle\u2010income countries March 2018. Geneva Switzerland: World Health Organization; 2018."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.04.002"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_6_8_1","unstructured":"Country profile: Cameroon.The World Bank Group. (Available from:https:\/\/data.worldbank.org\/country\/cameroon). [11 November 2019]."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12894"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/656233"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2006.10.003"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2008.02060.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20343"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025415"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2018.01.001"},{"key":"e_1_2_6_17_1","author":"Global hepatitis report. Geneva: World Health","year":"2017","journal-title":"Organization"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810477"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25050"},{"key":"e_1_2_6_20_1","unstructured":"NallR.How much does hepatitis C treatment cost?Medical News Today; 2018 (Available from:https:\/\/www.medicalnewstoday.com\/articles\/323767.php). [21 January 2020]."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2016-0037"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-017-0297-6"},{"key":"e_1_2_6_23_1","unstructured":"GustaffsonE Boggild\u2010JonesI SegallD DurlandJ.Impact bonds in developing countries: Early learnings from the field. Brookings; 2017. (Available from:https:\/\/www.brookings.edu\/research\/impact\u2010bonds\u2010in\u2010developing\u2010countries\u2010early\u2010learnings\u2010from\u2010the\u2010field\/). [6 February 2020]."},{"key":"e_1_2_6_24_1","unstructured":"GuarnaschelliS LampertS JohnsonL.Innovative financing for development: Scalable business models that produce economic social and environmental outcomes. Dalberg Global Development Advisors; 2014. Available from:https:\/\/www.convergence.finance\/resource\/3cMHyGn7nOkmUSciWuakyW\/view. [6 February 2020]."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-019-1214-9"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179562"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1276"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/mst197"},{"key":"e_1_2_6_29_1","unstructured":"Dimagi.CommCare: The world\u2019s most powerful mobile data collection platform. (Available from:https:\/\/www.dimagi.com\/commcare\/). [11 November 2019]."},{"key":"e_1_2_6_30_1","unstructured":"SchreinerM.Simple Poverty Scorecard Poverty\u2010Assessment Tool: Cameroon. 2016 (Available from:simplepovertyscorecard.com\/CMR_2014_ENG.pdf). [11 November 2019]."},{"key":"e_1_2_6_31_1","first-page":"1044","article-title":"Evaluation de l'observance du traitement antihypertenseur par un questionnaire: mise au point et utilisation dans un service sp\u00e9cialis\u00e9","volume":"30","author":"Girerd X","year":"2001","journal-title":"Presse Med"},{"key":"e_1_2_6_32_1","first-page":"2","article-title":"Therapeutic response of black africans in the treatment of genotype 2 chronic viral hepatitis c by pegylated interferon\u2010ribavirin.","volume":"1","author":"Njoya O","year":"2014","journal-title":"Austin J Gastroenterol"},{"key":"e_1_2_6_33_1","first-page":"1041","article-title":"Therapeutic response to pegylated interferon \u03b1\u20102a and ribavirin in genotype 4 chronic Hepatitis C in Sub Saharan Africans","volume":"3","author":"Njoya O","year":"2015","journal-title":"JSM Gastroenterol Hepatol"},{"key":"e_1_2_6_34_1","unstructured":"LacombeKMR ChazallonC SyllaBet al. Treatment of chronic hepatitis C GT1 2 3 in Africa: Final results of ANRS TAC trial. Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston Massachusetts."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30382-0"},{"key":"e_1_2_6_36_1","doi-asserted-by":"crossref","unstructured":"DebesJ SultanA BaneA.Treatment of hepatitis C genotypes 1 to 5 in Sub\u2010Saharan Africa using direct\u2010acting antivirals. Journal of Viral Hepatitis Special Issue: 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) held from June 14th to 17th 2018 in Toronto Canada. 2018;25(S2):159.","DOI":"10.1111\/jvh.221_12923"},{"key":"e_1_2_6_37_1","first-page":"10","article-title":"Traitement de l\u2019H\u00e9patite C de G\u00e9notype 1 par les Antiviraux d\u2019Action Directe au Cameroun : R\u00e9sultats Pr\u00e9liminaires","volume":"19","author":"Mairamou Hamadou N","year":"2018","journal-title":"Health Sci Dis"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.02.013"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4315-6"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1643160"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7122968"},{"key":"e_1_2_6_42_1","unstructured":"Guidelines for the screening care and treatment of persons with chronic hepatitis C infection April 2016. Geneva Switzerland: World Health Organization; 2016."},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.01.006"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315783"},{"key":"e_1_2_6_46_1","unstructured":"PharmAccess Foundation.HEP C\u2010IMPACT: Demonstrating feasibility of hepatitis C treatment through a social impact bond structure in Cameroon. 2016. (Available fromhttps:\/\/www.pharmaccess.org\/wp\u2010content\/uploads\/2017\/01\/ENG\u2010Hep\u2010C\u2010Impact\u2010demonstration\u2010project\u2010in\u2010Cameroon\u201006.12.2016.pdf). [11 November 2019]."},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30482-6"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftmi.13450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tmi.13450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T16:23:35Z","timestamp":1693931015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,5]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/tmi.13450"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13450","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,5]]},"assertion":[{"value":"2020-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}